文献速递乳腺癌

乳腺癌多基因风险评分与肿瘤特征及生存的关联

Associations of a Breast Cancer Polygenic Risk Score With Tumor Characteristics and Survival.
PubMed 文献 · J Clin Oncol · 2023-01-23

研究纳入BCAC中98,397例欧洲裔和12,920例亚洲裔浸润性乳腺癌女性及MINDACT试验683例女性,评估PRS313与临床病理特征及生存的关联。PRS313升高与更有利的肿瘤特征相关,校正临床病理特征和治疗后与总生存和乳腺癌特异性生存无独立关联。

要点

  • PRS313升高与更低分级、激素受体阳性及更小肿瘤大小相关。
  • 欧洲裔BCAC中PRS313较高者总生存和乳腺癌特异性生存较好,校正后关联消失。
  • PRS313在原发性乳腺癌诊断时无临床管理作用,但可用于分层筛查模型。

核心结论

  • PRS313升高与更有利的肿瘤特征相关,但与预后无独立关联。
  • PRS313在原发性乳腺癌诊断时无临床管理作用。
  • PRS313较高者乳腺癌死亡率更高,因PRS313升高与疾病风险增加相关,该信息对建模有效分层筛查方案至关重要。

研究设计与样本

  • 研究纳入来自乳腺癌协会联盟(BCAC)的98,397例欧洲裔和12,920例亚洲裔浸润性乳腺癌女性,以及来自欧洲MINDACT试验的683例女性。
  • 采用逻辑回归分析评估PRS313与临床病理特征(包括MINDACT的70基因特征)的关联。
  • 采用Cox回归评估PRS313(连续变量,每标准差)与总生存(OS)和乳腺癌特异性生存(BCSS)的关联,校正临床病理特征和治疗。

主要发现

  • 在BCAC中,PRS313升高与更低分级、激素受体阳性状态和更小肿瘤大小相关。
  • 在MINDACT中,PRS313与低风险70基因特征相关。
  • 在BCAC欧洲裔女性中,PRS313较高与更好的OS和BCSS相关:HR 0.96(95%CI 0.94至0.97)和HR 0.96(95%CI 0.94至0.98)。
  • 校正临床病理特征(和治疗)后关联消失:OS HR 1.01(95%CI 0.98至1.05),BCSS HR 1.02(95%CI 0.98至1.07)。
  • MINDACT和BCAC亚洲裔女性的结果一致。

临床怎么用

  • PRS313在原发性乳腺癌诊断时无临床管理作用。
  • PRS313较高者乳腺癌死亡率更高,因PRS313升高与疾病风险增加相关,该信息对建模有效分层筛查方案至关重要。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: A polygenic risk score (PRS) consisting of 313 common genetic variants (PRS313) is associated with risk of breast cancer and contralateral breast cancer. This study aimed to evaluate the association of the PRS313 with clinicopathologic characteristics of, and survival following, breast cancer. METHODS: Women with invasive breast cancer were included, 98,397 of European ancestry and 12,920 of Asian ancestry, from the Breast Cancer Association Consortium (BCAC), and 683 women from the European MINDACT trial. Associations between PRS313 and clinicopathologic characteristics, including the 70-gene signature for MINDACT, were evaluated using logistic regression analyses. Associations of PRS313 (continuous, per standard deviation) with overall survival (OS) and breast cancer-specific survival (BCSS) were evaluated with Cox regression, adjusted for clinicopathologic characteristics and treatment. RESULTS: The PRS313 was associated with more favorable tumor characteristics. In BCAC, increasing PRS313 was associated with lower grade, hormone receptor-positive status, and smaller tumor size. In MINDACT, PRS313 was associated with a low risk 70-gene signature. In European women from BCAC, higher PRS313 was associated with better OS and BCSS: hazard ratio (HR) 0.96 (95% CI, 0.94 to 0.97) and 0.96 (95% CI, 0.94 to 0.98), but the association disappeared after adjustment for clinicopathologic characteristics (and treatment): OS HR, 1.01 (95% CI, 0.98 to 1.05) and BCSS HR, 1.02 (95% CI, 0.98 to 1.07). The results in MINDACT and Asian women from BCAC were consistent. CONCLUSION: An increased PRS313 is associated with favorable tumor characteristics, but is not independently associated with prognosis. Thus, PRS313 has no role in the clinical management of primary breast cancer at the time of diagnosis. Nevertheless, breast cancer mortality rates will be higher for women with higher PRS313 as increasing PRS313 is associated with an increased risk of disease. This information is crucial for modeling effective stratified screening programs.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Lopes Cardozo JMN, Andrulis IL, Bojesen SE, et al. Associations of a Breast Cancer Polygenic Risk Score With Tumor Characteristics and Survival. J Clin Oncol. 2023. PMID: 36689693. doi:10.1200/JCO.22.01978

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。